1. Claim 1: a method for dealing with a disease or disease affected by the performance or activity of PCBs, including: treating an antibody or part of its antigen binding； Specifically, hpcsk9 (protein transform ASA subtilisin A / kexina-9 human) was added to a person in need, where antibodies or fragments bound to the same antigen were administered in a dose range of 5 mg to 500 mg. And the subjects were given an inhibitor of reduced HMG-CoAHMG-CoA reducing inhibitor 2: antibody or part of antigen added in it was administered in the dose range of 0.05 mg to 100 mg； Specifically, hpcsk9 (protein transform ASA subtilisina / kexina-9 human) was added to treat the diseases or conditions affected by the performance or activities of PCSK9, When an antibody or part of an antibody is used in doses ranging from 5 mg to 500 mg,(i) In addition to antibodies, antibodies that bind antibodies, or part of them, to antibodies will be used in combination with an HMG-CoA inhibitor that is reduced in a dose range from 0.05 mg to 100 mg. 119. Claim 23, including (a) finished product of packaging material； (b) antibody or binding part of the same antigen specially connected with hpcsk9；The labels or instructions in the Y (c) packaging materials indicate that patients who receive the treatment of this antibody or antigen binding fragment can treat a specific disease or disease composed of high cholesterol, high blood fat, degreasing, etc, Myocardial infarction and cardiovascular disease Claim 36: a method for preventing (persistently) high LDL content from affecting blood, including: treatment of antibodies or parts of antibody binding；Specifically, hpcsk9 (protein transform ASA subtilisin A / kexina-9 human) was added to a person in need, where antibodies or fragments bound to the same antigen were administered in a dose range of 5 mg to 500 mg. The subjects were treated with a reduced HMG-CoA inhibitor in the range of 0.05 mg to 100 mg.Reivindicación 1: Un método para tratar una enfer
